Table 1: Inhibitory concentration 50 (IC50) of the major pharmaceutical compounds in clinical development for the treatment of thyroid cancer segregated with respect to the kinase activity required to inhibit different molecular targets (nmol/L).

Pharmaceutical compound VEGFR1 VEGFR2 VEGFR3 RET RET/PTC PDGFRβ BRAF KIT Others (IC50) Sorafenib 26 90 20 47 50 57 25 68 — Motesanib 2 3 6 59 — 84 — 8 — Axitinib 0.1 0.2 0.29 1.2 — 2 — 1.7 — Sunitinib 10 10 10 100 224 39 — 1–10 — Vandetanib — 40 110 130 100 — — — EGFR (500) Pazopanib 10 30 47 — — 84 — 74 — Lenvatinib (E7080) 22 4 5.2 35 — 39 — — FGFR1 (46) Cabozantinib (XL-184) — 0.035 — 4 — — — — C-MET (1.8)